- Home
- HSHP vs CDXS Comparison
HSHP vs CDXS Comparison
Compare HSHP & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- CDXS
- Stock Information
- Founded
- HSHP 2021
- CDXS 2002
- Country
- HSHP Bermuda
- CDXS United States
- Employees
- HSHP N/A
- CDXS N/A
- Industry
- HSHP
- CDXS Major Chemicals
- Sector
- HSHP
- CDXS Industrials
- Exchange
- HSHP Nasdaq
- CDXS Nasdaq
- Market Cap
- HSHP 268.6M
- CDXS 216.6M
- IPO Year
- HSHP 2023
- CDXS 2010
- Fundamental
- Price
- HSHP $8.02
- CDXS $2.56
- Analyst Decision
- HSHP
- CDXS Buy
- Analyst Count
- HSHP 0
- CDXS 2
- Target Price
- HSHP N/A
- CDXS $11.00
- AVG Volume (30 Days)
- HSHP 188.9K
- CDXS 538.3K
- Earning Date
- HSHP 11-20-2025
- CDXS 10-30-2025
- Dividend Yield
- HSHP 5.62%
- CDXS N/A
- EPS Growth
- HSHP N/A
- CDXS N/A
- EPS
- HSHP 0.14
- CDXS N/A
- Revenue
- HSHP $120,680,000.00
- CDXS $57,164,000.00
- Revenue This Year
- HSHP $7.72
- CDXS $12.88
- Revenue Next Year
- HSHP $27.02
- CDXS $21.64
- P/E Ratio
- HSHP $60.32
- CDXS N/A
- Revenue Growth
- HSHP 44.77
- CDXS N/A
- 52 Week Low
- HSHP $4.29
- CDXS $1.90
- 52 Week High
- HSHP $8.95
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- HSHP 43.10
- CDXS 51.47
- Support Level
- HSHP $8.14
- CDXS $2.41
- Resistance Level
- HSHP $8.39
- CDXS $2.73
- Average True Range (ATR)
- HSHP 0.18
- CDXS 0.12
- MACD
- HSHP -0.11
- CDXS 0.03
- Stochastic Oscillator
- HSHP 9.31
- CDXS 55.26
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.